KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Net Cash Flow (2016 - 2025)

Neogenomics (NEO) has disclosed Net Cash Flow for 16 consecutive years, with -$4.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow fell 190.26% year-over-year to -$4.5 million, compared with a TTM value of -$207.4 million through Dec 2025, down 945.68%, and an annual FY2025 reading of -$207.4 million, down 945.68% over the prior year.
  • Net Cash Flow was -$4.5 million for Q4 2025 at Neogenomics, down from $9.4 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $372.5 million in Q1 2021 and bottomed at -$250.2 million in Q2 2021.
  • Average Net Cash Flow over 5 years is -$4.6 million, with a median of -$3.7 million recorded in 2022.
  • The sharpest move saw Net Cash Flow surged 1330.45% in 2023, then crashed 926.11% in 2025.
  • Year by year, Net Cash Flow stood at -$26.9 million in 2021, then skyrocketed by 89.05% to -$2.9 million in 2022, then soared by 1330.45% to $36.2 million in 2023, then tumbled by 86.15% to $5.0 million in 2024, then tumbled by 190.26% to -$4.5 million in 2025.
  • Business Quant data shows Net Cash Flow for NEO at -$4.5 million in Q4 2025, $9.4 million in Q3 2025, and -$191.4 million in Q2 2025.